Maridebart Cafraglutide
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SW
Amgen · Phase 3 · Recruiting · Enrollment 300
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.